Trial Profile
An Open Label Study of Abiraterone Acetate in Subjects With Metastatic Castration-Resistant Prostate Cancer Who Have Progressed After Taxane-Based Chemotherapy
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Jan 2022
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Registrational
- Sponsors Janssen Research & Development; Janssen-Cilag
- 14 Mar 2016 Results of post-hoc analysis published in the Janssen Cilag media release.
- 03 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 02 Oct 2015 Planned End Date changed from 1 Jul 2015 to 1 Oct 2015, as reported by ClinicalTrials.gov.